
News|Articles|February 1, 2011
FDA Pipeline Preview, February 2011 (Afrezza, Nuvigil, Opana ER, Liprotamase, Erwinaze, Telaprevir, SNS01-T, XL184, QLT091001, Fidaxomicin)
Recent FDA action (through, January 2011) related to Afrezza, Nuvigil, Opana ER, Liprotamase, Erwinaze, Telaprevir, SNS01-T, XL184, QLT091001, Fidaxomicin.
Advertisement
Complete response
Not recommended for approval
Priority review
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
Cancer survival fell and deaths rose during first two years of COVID-19
3
PBM reform. It has finally happened
4
TrumpRx launches; some experts question its long-term value
5

























